Pharmaceuticals company Supriya Lifescience announced Q3FY26 results Revenue: Rs 2,064.4 million against Rs 1,856.5 million during Q3FY25, change 11%. EBITDA: Rs 720.8 million against Rs 659.6 million during Q3FY25, change 9%. EBITDA Margin: 34.9% for Q3FY26. PBT: Rs 669.2 million against Rs 625.9 million during Q3FY25, change 7%. PAT: Rs 496.8 million against Rs 467.8 million during Q3FY25, change 6%. PAT Margin: 24.1% for Q3FY26. EPS: Rs 6.2 for Q3FY26. Result PDF